Melanoma Survivors: Health Behaviors, Surveillance, Psychosocial Factors, and Family Concerns
[Protocol 06-128] |
Oliveria, Susan, ScD, MPH |
An Evaluation of Perceptions and Quality of Life Among Patients Receiving Ipilimumab for Melanoma
[Protocol 11-184] |
Hay, Jennifer, PhD |
A Study of the Biologic Effects of BMS-936558 in Patients with Inoperable or Metastatic Melanoma
[Protocol 12-231] |
Wolchok, Jedd, MD, PhD |
A Phase III Study of Vemurafenib in Patients with Surgically Removed BRAF-Mutant Melanoma Who Have a High Risk of Recurrence
[Protocol 12-166] |
Chapman, Paul, MD |
A Phase III Study of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy in Patients with Cutaneous Melanomas that Have Metastasized to the Sentinel Node
[Protocol 09-112] |
Ariyan, Charlotte, MD |
A Phase III Study of Nilotinib (Tasigna®) versus Dacarbazine in Patients with Advanced Melanoma with a c-Kit Mutation (TEAM Trial
[Protocol 10-102] |
Carvajal, Richard, MD |
A Phase III Study of BMS-936558 versus Standard Chemotherapy in Patients with Advanced Melanoma that Progressed Despite Anti-CTLA-4 Therapy
[Protocol 12-254] |
D'Angelo, Sandra, MD |
A Phase II Trial of Temozolomide versus AZD6244 in Patients with Metastatic Uveal Melanoma
[Protocol 10-053] |
Carvajal, Richard, MD |
A Phase II Study of Vorinostat for Metastatic Uveal Melanoma
[Protocol 12-027] |
Carvajal, Richard, MD |
A Phase II Study of RAD001 (Everolimus) and Pasireotide (SOM230)) in Patients with Advanced Uveal Melanoma
[Protocol 10-123] |
Carvajal, Richard, MD |
A Phase II Study of Ipilimumab Plus Isolated Limb Infusion with Melphalan and Dactinomycin to Treat Advanced Unresectable Melanoma of the Extremity
[Protocol 10-101] |
Ariyan, Charlotte, MD |
A Phase II Study of Ipilimumab in Children and Adolescents with Stage III/IV Inoperable Melanoma
[Protocol 13-043] |
Dunkel, Ira, MD |
A Phase II Study of Dabrafenib After Surgery in Patients with BRAF V600 Mutation-Positive Stage IIIC Melanoma
[Protocol 12-124] |
Chapman, Paul, MD |
A Phase Ib Study of MDX-1106 (BMS-936558) in Combination with Ipilimumab (BMS-734016) in Patients with Unresectable Stage III or Stage IV Malignant Melanoma
[Protocol 09-155] |
Wolchok, Jedd, MD, PhD |
A Phase I Study of Vemurafenib in Adolescents with Inoperable Stage IIIC/IV Melanoma with V600 BRAF Mutations
[Protocol 11-198] |
Pratilas, Christine, MD |
A Phase I Study of the NY-ESO-1 Vaccine plus Ipilimumab in Patients with Inoperable or Metastatic Melanoma
[Protocol 12-253] |
Wolchok, Jedd, MD, PhD |
A Phase I Study of Ipilimumab in Children, Adolescents, and Young Adults with Treatment-Refractory Cancer
[Protocol 10-193] |
Wexler, Leonard, MD |
A Phase I Study of BMS-986015 with Ipilimumab in Patients with Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Melanoma
[Protocol 12-283] |
Rizvi, Naiyer, MD |
A Phase I Study of BMS-986015 plus BMS-936558 in Patients with Advanced Solid Tumors
[Protocol 12-224] |
Segal, Neil, MD, PhD |
A Phase I Study of an mRNA-Modified Dendritic Cell Vaccine in Patients with Melanoma
[Protocol 10-229] |
Young, James, MD |
A Phase I Study of AMP-224 with a Cyclophosphamide-Containing Regimen in Patients with Advanced Melanoma
[Protocol 12-127] |
Dickson, Mark, MD |
A Phase I Study of AEB071 in Patients with Metastatic Uveal Melanoma
[Protocol 11-167] |
Schwartz, Gary, MD |
